TOPOⅡ、ERCC1、MDR1、PTEN、Livin基因在上皮性卵巢癌中的表达及其临床意义
|
摘要
目的:通过分析TOPOII、ERCC1、MDR1、PTEN、Livin在81例上皮性卵巢癌中的表达,探讨其与上皮性卵巢癌病理类型、临床分期、组织学分级、化疗耐药及预后的关系。
方法:对81例上皮性卵巢癌患者的临床病理资料进行回顾性分析。应用SPSS13.0统计软件,采用Kaplan-Meier方法计算生存率并绘制生存曲线,log-rank检验进行生存率差异的单因素分析,多因素分析采用Cox回归模型,相关性分析采用Spearman等级相关,计数资料采用χ2检验,均以P<0.05为差异有统计学意义。
结果:
1不同年龄段组织学分级差异有统计学意义(P<0.05)。<55岁组组织学分级低;≥55岁组组织学分级高。
2单因素分析:耐药相关基因TOPOII、ERCC1的表达、治疗方法、手术方式是影响上皮性卵巢癌预后的相关因素(P<0.05)。TOPOII、ERCC1高表达,手术辅以术后化疗,行肿瘤细胞减灭术和或淋巴结清扫者生存率高。多因素回归分析表明:病理类型、手术-病理分期、组织学分级、耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达、淋巴结清扫、淋巴结转移、手术范围、治疗方法均不是影响上皮性卵巢癌预后的独立危险因素。
3耐药相关基因与上皮性卵巢癌组织学分级、病理类型、手术-病理分期及化疗耐药的关系
TOPOII、ERCC1、MDR1、PTEN、Livin的表达在上皮性卵巢癌化疗耐药组与敏感组之间无明显统计学差异(P>0.05),在不同的组织学分级、病理类型、手术-病理分期中其表达无明显统计学差异(P>0.05)。
4淋巴结转移相关临床病理因素比较,年龄、病理类型、组织学分级无明显统计学差异(P均>0.05)。
5耐药相关基因表达的相关性
TOPOII与ERCC1两者的表达具有负相关性(r=-0.447,P<0.001),TOPOII与MDR1两者的表达具有负相关性(r=-0.159,P<0.05),TOPOII与PTEN两者的表达具有负相关性(r=-0.775,P<0.001),TOPOII与Livin两者的表达具有负相关性(r=-0.476,P<0.001);ERCC1与MDR1的表达呈正相关(r=0.322,P<0.001),ERCC1与PTEN的表达呈负相关(r=-0.404,P<0.001),ERCC1与Livin的表达无相关性(r=-0.037,P=0.636);MDR1与PTEN的表达呈负相关(r=-0.681,P<0.001)、MDR1与Livin的表达呈负相关(r=-0.456,P<0.001);PTEN与Livin的表达呈正相关(r=0.369,P<0.001)。
结论:
1上皮性卵巢癌组织细胞分化与年龄相关,年轻者组织分化差。
2耐药相关基因TOPOII、ERCC1的表达、治疗方法、手术范围是影响上皮性卵巢癌预后的相关危险因素。
3病理类型、手术-病理分期、组织学分级、耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达、淋巴结清扫、淋巴结转移、手术范围、治疗方法均不是影响上皮性卵巢癌预后的独立危险因素。
4耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达与上皮性卵巢癌的病理类型、手术-病理分期、组织学分级及化疗耐药与否无明显相关性。
5组织学分级、年龄、病理类型不是淋巴结转移的危险因素。
6上皮性卵巢癌中TOPOII与ERCC1、MDR1、PTEN、Livin的表达呈负相关; ERCC1与MDR1的表达呈正相关,与PTEN的表达呈负相关,与Livin的表达无相关性;MDR1与PTEN、Livin的表达呈负相关;PTEN与Livin的表达呈正相关。耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的不同表达在上皮性卵巢癌的发生发展中可能具有相互协同、相互拮抗的关系。
Objective: TO study the expressions of TOPOII,ERCC1,MDR1,PTEN and Livin in the epithelial ovarian cancer tissues.TO evaluate the relationship between their expressions and pathologic type,operation-pathological stage,histological grade,chemotherapy resistance and the prognosis of epithelial ovarian cancer.
Methods: To analyze retrospectively the clinical information of 81 patients with epithelial ovarian cancer.
SPSS 13.0 software package was used. Using Kaplan-Meier method to calculate Survival rates and draw survival curve. Univariate analysis between different Survivorship rates was estimated by log-rank test. Multiple regression analysis were assessed by Cox proportional hazards model. Dependablity analysis was estimated by Spearman rank correlation. Enumeration data were compared withχ2 test.A statistically significant difference was indicated by P<0.05.
Results:
1 There are significant differences in histological type between the different age groups (P<0.05). The≥55 group has well differentiated,while the <55group has countrary results.
2 Univariate analysis revealed that the expressions of TOPOII and ERCC1,treatment modality,operation circumsciption are significantly associated with the overall-survival of patients in epithelial ovarian cancer. The prognosis of the patients who have high expressions of TOPOII and ERCC1,enforced operation associated with chemotherapy and have exterminated tumor cell and lymph node cleaning operation are better.
Multivariate analysis revealeds that pathologic type,operation- pathological stage,histological grade,expressions of drug fast related gene TOPOII,ERCC1, MDR1,PTEN and Livin,lymph node cleaning,lymph node metastasis, operation circumsciption,treatment modality are not independent risk factors for the prognosis of epithelial ovarian cancer.
3 Relationship between drug fast related gene and pathologic type, operation- pathological stage,histological grade,chemotherapy resistance of epithelial ovarian cancer.
There are no significant differences in the expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN,Livin between chemotherapy resistance group and chemotherapy Sensitive group(P>0.05).And there are no significant differences between their expressions and different pathologic type,operation-pathological stage,histological grade(P>0.05).
4 Comparison of various clinicopathologic factor related to lymph node metastasis,there are not significant differences in age,histological grade,pathologic type,operation-pathological stage(P>0.05).
5 Correlation between the expressions of these drug fast related gene
The expressions between TOPOII and ERCC1 shows negative correlation(r=-0.447,P<0.001),the expressions between TOPOII and MDR1 shows negative correlation(r=-0.159,P<0.05),the expressions between TOPOII and PTEN shows negative correlation(r=-0.775,P<0.001),the expressions between TOPOII and Livin shows negative correlation(r=-0.476,P<0.001);the expressions between ERCC1 and MDR1 shows positive correlation(r=0.322,P<0.001);the expressions between ERCC1 and PTEN shows negative correlation(r=-0.404,P<0.001);the expressions between ERCC1 and Livin shows no correlation(r=-0.037,P=0.636>0.05);the expressions between MDR1 and PTEN shows negative correlation(r=-0.681,P<0.001 ) ;the expressions between MDR1 and Livin shows negative correlation(r=-0.456,P<0.001);the expressions between PTEN and Livin shows positive correlation(r=0.369,P<0.001).
Conclusion:
1 Histological grade is correlated with the patient's age in epithelial ovarian cancer,when the patient's age is lower,the histological grade is worse.
2 The expressions of TOPOII and ERCC1,treatment modality,operation circumsciption are correlative risk factors for the prognosis of epithelial ovarian cancer.
3 Pathologic type,operation-pathological stage,histological grade,expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN and Livin, lymph node cleaning,lymph node metastasis,operation circumsciption,treatment modality are not independent risk factors for the prognosis of epithelial ovarian cancer.
4 Expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN and Livin are not significantly correlated with the pathologic type, operation- pathological stage,histological grade and chemotherapy resistance of epithelial ovarian cancer.
5 Histological grade,age and pathologic type are not risk facors for lymph node metastasis in epithelial ovarian cancer.
6 In epithelial ovarian cancer,the expressions between TOPOII and ERCC1, MDR1,PTEN,Livin shows negative correlation;the expressions between ERCC1 and MDR1 shows positive correlation;the expressions between ERCC1 and PTEN shows negative correlation;the expressions between ERCC1 and Livin shows no correlation;the expressions between MDR1 and PTEN,Livin shows negative correlation;the expressions between PTEN and Livin shows positive correlation.
The different expressions of TOPOII,ERCC1,MDR1,PTEN and Livin may produce a cooperation or antagonistic effect with the development of epithelial ovarian cancer tissues.
方法:对81例上皮性卵巢癌患者的临床病理资料进行回顾性分析。应用SPSS13.0统计软件,采用Kaplan-Meier方法计算生存率并绘制生存曲线,log-rank检验进行生存率差异的单因素分析,多因素分析采用Cox回归模型,相关性分析采用Spearman等级相关,计数资料采用χ2检验,均以P<0.05为差异有统计学意义。
结果:
1不同年龄段组织学分级差异有统计学意义(P<0.05)。<55岁组组织学分级低;≥55岁组组织学分级高。
2单因素分析:耐药相关基因TOPOII、ERCC1的表达、治疗方法、手术方式是影响上皮性卵巢癌预后的相关因素(P<0.05)。TOPOII、ERCC1高表达,手术辅以术后化疗,行肿瘤细胞减灭术和或淋巴结清扫者生存率高。多因素回归分析表明:病理类型、手术-病理分期、组织学分级、耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达、淋巴结清扫、淋巴结转移、手术范围、治疗方法均不是影响上皮性卵巢癌预后的独立危险因素。
3耐药相关基因与上皮性卵巢癌组织学分级、病理类型、手术-病理分期及化疗耐药的关系
TOPOII、ERCC1、MDR1、PTEN、Livin的表达在上皮性卵巢癌化疗耐药组与敏感组之间无明显统计学差异(P>0.05),在不同的组织学分级、病理类型、手术-病理分期中其表达无明显统计学差异(P>0.05)。
4淋巴结转移相关临床病理因素比较,年龄、病理类型、组织学分级无明显统计学差异(P均>0.05)。
5耐药相关基因表达的相关性
TOPOII与ERCC1两者的表达具有负相关性(r=-0.447,P<0.001),TOPOII与MDR1两者的表达具有负相关性(r=-0.159,P<0.05),TOPOII与PTEN两者的表达具有负相关性(r=-0.775,P<0.001),TOPOII与Livin两者的表达具有负相关性(r=-0.476,P<0.001);ERCC1与MDR1的表达呈正相关(r=0.322,P<0.001),ERCC1与PTEN的表达呈负相关(r=-0.404,P<0.001),ERCC1与Livin的表达无相关性(r=-0.037,P=0.636);MDR1与PTEN的表达呈负相关(r=-0.681,P<0.001)、MDR1与Livin的表达呈负相关(r=-0.456,P<0.001);PTEN与Livin的表达呈正相关(r=0.369,P<0.001)。
结论:
1上皮性卵巢癌组织细胞分化与年龄相关,年轻者组织分化差。
2耐药相关基因TOPOII、ERCC1的表达、治疗方法、手术范围是影响上皮性卵巢癌预后的相关危险因素。
3病理类型、手术-病理分期、组织学分级、耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达、淋巴结清扫、淋巴结转移、手术范围、治疗方法均不是影响上皮性卵巢癌预后的独立危险因素。
4耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的表达与上皮性卵巢癌的病理类型、手术-病理分期、组织学分级及化疗耐药与否无明显相关性。
5组织学分级、年龄、病理类型不是淋巴结转移的危险因素。
6上皮性卵巢癌中TOPOII与ERCC1、MDR1、PTEN、Livin的表达呈负相关; ERCC1与MDR1的表达呈正相关,与PTEN的表达呈负相关,与Livin的表达无相关性;MDR1与PTEN、Livin的表达呈负相关;PTEN与Livin的表达呈正相关。耐药相关基因TOPOII、ERCC1、MDR1、PTEN、Livin的不同表达在上皮性卵巢癌的发生发展中可能具有相互协同、相互拮抗的关系。
Objective: TO study the expressions of TOPOII,ERCC1,MDR1,PTEN and Livin in the epithelial ovarian cancer tissues.TO evaluate the relationship between their expressions and pathologic type,operation-pathological stage,histological grade,chemotherapy resistance and the prognosis of epithelial ovarian cancer.
Methods: To analyze retrospectively the clinical information of 81 patients with epithelial ovarian cancer.
SPSS 13.0 software package was used. Using Kaplan-Meier method to calculate Survival rates and draw survival curve. Univariate analysis between different Survivorship rates was estimated by log-rank test. Multiple regression analysis were assessed by Cox proportional hazards model. Dependablity analysis was estimated by Spearman rank correlation. Enumeration data were compared withχ2 test.A statistically significant difference was indicated by P<0.05.
Results:
1 There are significant differences in histological type between the different age groups (P<0.05). The≥55 group has well differentiated,while the <55group has countrary results.
2 Univariate analysis revealed that the expressions of TOPOII and ERCC1,treatment modality,operation circumsciption are significantly associated with the overall-survival of patients in epithelial ovarian cancer. The prognosis of the patients who have high expressions of TOPOII and ERCC1,enforced operation associated with chemotherapy and have exterminated tumor cell and lymph node cleaning operation are better.
Multivariate analysis revealeds that pathologic type,operation- pathological stage,histological grade,expressions of drug fast related gene TOPOII,ERCC1, MDR1,PTEN and Livin,lymph node cleaning,lymph node metastasis, operation circumsciption,treatment modality are not independent risk factors for the prognosis of epithelial ovarian cancer.
3 Relationship between drug fast related gene and pathologic type, operation- pathological stage,histological grade,chemotherapy resistance of epithelial ovarian cancer.
There are no significant differences in the expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN,Livin between chemotherapy resistance group and chemotherapy Sensitive group(P>0.05).And there are no significant differences between their expressions and different pathologic type,operation-pathological stage,histological grade(P>0.05).
4 Comparison of various clinicopathologic factor related to lymph node metastasis,there are not significant differences in age,histological grade,pathologic type,operation-pathological stage(P>0.05).
5 Correlation between the expressions of these drug fast related gene
The expressions between TOPOII and ERCC1 shows negative correlation(r=-0.447,P<0.001),the expressions between TOPOII and MDR1 shows negative correlation(r=-0.159,P<0.05),the expressions between TOPOII and PTEN shows negative correlation(r=-0.775,P<0.001),the expressions between TOPOII and Livin shows negative correlation(r=-0.476,P<0.001);the expressions between ERCC1 and MDR1 shows positive correlation(r=0.322,P<0.001);the expressions between ERCC1 and PTEN shows negative correlation(r=-0.404,P<0.001);the expressions between ERCC1 and Livin shows no correlation(r=-0.037,P=0.636>0.05);the expressions between MDR1 and PTEN shows negative correlation(r=-0.681,P<0.001 ) ;the expressions between MDR1 and Livin shows negative correlation(r=-0.456,P<0.001);the expressions between PTEN and Livin shows positive correlation(r=0.369,P<0.001).
Conclusion:
1 Histological grade is correlated with the patient's age in epithelial ovarian cancer,when the patient's age is lower,the histological grade is worse.
2 The expressions of TOPOII and ERCC1,treatment modality,operation circumsciption are correlative risk factors for the prognosis of epithelial ovarian cancer.
3 Pathologic type,operation-pathological stage,histological grade,expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN and Livin, lymph node cleaning,lymph node metastasis,operation circumsciption,treatment modality are not independent risk factors for the prognosis of epithelial ovarian cancer.
4 Expressions of drug fast related gene TOPOII,ERCC1,MDR1,PTEN and Livin are not significantly correlated with the pathologic type, operation- pathological stage,histological grade and chemotherapy resistance of epithelial ovarian cancer.
5 Histological grade,age and pathologic type are not risk facors for lymph node metastasis in epithelial ovarian cancer.
6 In epithelial ovarian cancer,the expressions between TOPOII and ERCC1, MDR1,PTEN,Livin shows negative correlation;the expressions between ERCC1 and MDR1 shows positive correlation;the expressions between ERCC1 and PTEN shows negative correlation;the expressions between ERCC1 and Livin shows no correlation;the expressions between MDR1 and PTEN,Livin shows negative correlation;the expressions between PTEN and Livin shows positive correlation.
The different expressions of TOPOII,ERCC1,MDR1,PTEN and Livin may produce a cooperation or antagonistic effect with the development of epithelial ovarian cancer tissues.
引文
1 Jemal A,Siegel R, Ward E,etal.Cancer statistics[J].CA Cancer J Clin,2006,56:106
2焦伊胜,王永来,张淑兰,等. Livin、Smac在上皮性卵巢癌中的表达及意义.妇科肿瘤,2009,17(2):296-299
3 Qazi F,McGuire WP.The treatment of epithlial ovarian cancer.CA cancer JClin,1995,45:88
4郄明蓉,张崇淑,杨小芸,等.10年间卵巢上皮性癌的治疗及预后因素分析[J].华西医学,2002(3):312-314
5周凤志,陈毅男,张国男,等.不同年龄段卵巢上皮性癌的临床病理分析[J].四川肿瘤防治,2003(4):197-200
6宋水勤,张国楠,吴艳丽,等.卵巢上皮性癌生存率及预后因素分析[J].现代妇产科进展,2001(4):250-253
7张洁清,余冬青,李力,等.影响卵巢癌预后的多因素分析.广西医科大学学报,2004,21(5):687-689
8关珊,李永辉,宋鸿碧,等.上皮性卵巢癌生存率及预后因素分析.贵阳医学院学报.2007,32(2):177-178
9张桂荣,翟云起,杜少敏,等.卵巢上皮癌治疗及预后影响因素研究[ J].肿瘤学杂志, 2003(2) : 68- 70
10 Mackay HJ,Brady MF,Oza AM, etal. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010 Aug;20(6):945-52
11臧荣余,张志毅,李子庭,等.晚期上皮性卵巢癌的预后影响因素.复旦学报(医学科学版),2001,28(1):47-50
12王世阆,张崇淑,彭红琪,等. 135例卵巢上皮癌的治疗及其预后因素.中华妇产科杂志,1991,26: 86
13 Clark TG,Stew art ME,Altman DG,etal.A prognostic model for ovarian cancer.B r J Cancer,2001,85(7):944-952
14 Brun JL,Feyler A,Chene G,etal.Long term results and prognostic factors in patients With epithelial ovarian cancer.Gynecol Oncol,2000,78(1):21-27
15罗中明,郭振仪,阮晓红,等.晚期上皮性卵巢癌预后的相关因素分析.临床合理用药,2008,2(16):31-33
16杨幼易,蔡树模.应用Cox模型对上皮性卵巢癌的预后分析.中国医学文摘·肿瘤学,2001,15(3):280-281
17 Petru E,Lahousen M,Tamussino K,etal.Lymphadenectomy in stage 1 ovarian cancer. Am J Obstet Gynecol,1994,170(2):656-662
18 Parazzini F,Valsecchi G,Bolis G,etal.Pelvic and paraortic lymphnodal status in advanced ovarian cancer and survival.Gynecol Oncol,1999,74(1):7-11
19 Scarabelli C,Gallo A,Zamelli A,etal.Systematic pelvic and paraorticlymphadenectomy during cytoreductive surgery in advanced ovanrian cancer:potential benefit on survival. Gynecol Oncol,1995,58(3):417
20熊宙芳,王泽华,王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产科杂志, 2003, 38 (2) : 77-80
21 Kikkawa F,Ishikawa H,Tamakoshi K,etal.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995, 60(4):227-231
22 Soygili I,Gnclu S,CsJu T,etal.Does Systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma?A DEGOG Study. J Surg Oncol,2002,81(3):132-137
23 Barber HRK.Symposium on ovarian tumors:foreword[J].Clin Obstet Gynecol,1996,12:929
24王建.上皮性卵巢癌预后因素分析.天津医科大学学报,2005,11(2):260
25 Bristow TE,Tomacruz TS,A rmstrong DK,etal. Survival effect of maximal cyto reductive surgery for advanced ovarian carcinoma during the platinumera:A meta analysis. J Clin O nco l,2002,20 (5):1248-1259
26吴玉,王秋宇.46例上皮性卵巢癌的临床及预后分析.中国实用医药,2008,3(1):90-91
27关珊,宋鸿碧,文萍,等.术后化疗对上皮性卵巢癌预后的影响.贵阳医学院学报,2006,31(6):563-566
28 Ito K,Yabuki N,Sasano H,etal.Immunohistochemical study of Ki67 and DNA topisomerase II in human endometrium [J],Mod Pathol,1997, 10(4): 289-294
29傅士龙,张国玲,李子庭,等.卵巢癌拓扑异构酶TOPOIIα表达与化疗敏感性的关系.现在妇产科进展,2002,11(4):245-247
30 30Gotlieb WH,Goldberg I,Weise B,etal.Topoisomerase II Immunostaining as a Prognostic maker for survival in ovarian cancer[J].Gynecol Oncol, 2001,82(1):99-104
31卢培刚,朱树干,刘玉光.DNA拓扑异构酶II在人脑胶质瘤中的表达及临床意义.中国神经精神疾病杂志,2002 ,28(5):380-381
32郭威,宋光,吴国新,等.GST-P、P-gp及TopoII在大肠癌中的表达及其多药耐药的临床研究.齐齐哈尔医学院学报，2007，28（3）：269-271
33邓刚，杨成章，陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义.临床耳鼻咽喉科杂志.2005,19（9）：396-398
34邹倩,石王伟,黄利鸣，等.拓扑异构酶 在宫颈癌组织中的表达及其临床意义.肿瘤防治研究，2003，30（3）：196-197
35 Andrea JE,Adachi K,Morgan AR.Fluorometric assays for DNA topoisomerasesand topoisomerase targeted drugs;quantitation of catalyticactivity and DNA clearage [J].Mol Pharmacol,1991,40 (4):495-501
36 Staley BE,Samowitz WS,Bronstein IB,etal.Expression of DNAtopoisomerase I and DNA topoisomerase II-alpha in carcinoma of thecolon[J] .Mod Pathol,1999,12 (4):356-361
37蒋胜，李力，张玮，等.ERCC1基因mRNA表达水平在卵巢癌上皮性癌组织中的意义.实用妇产科杂志.2009,25(11)：661-663
38 Simth S,Su D,Rigault de la Longrais IA,etal.ERCC1 genotype andphenotype in epithlial ovarian cancer identify pantients likely to benefitfrom paclitaxel treatment in addition to platinim-based therapy[J].J ClinOncol,2007,25(33):5172-5179
39李琳，许崇安，田大力，等.非小细胞肺癌组织ERCC1表达及其与预后相关性的分析.中华肿瘤防治杂志，2010，17（3）：186-190
40 Ceppi P,Volante M,Novello S,etal.ERCC1 and RRM1 gene expressions butEGFR are predictive of shorter survival in advanced non-small-cell lungcancer treated with cispltin and gemcitabine[J]. Ann Oncol,2006,17(12) :1818-1825
41 Azuma K,Komohara Y,Sasada Z,etal. Excision repair crosscomplementation group 1 predicts progression-free and overall survival in non-smallcelllung cancer patients treated with platinumbased chemotherapy[J].Cancer Sci,2007,98(9):1336-1343
42 Zheng Z,Chen T,Li X,etal. DNA synthesis and repair genes RRM1 andERCC1 in lung cancer[J]. N Engl J Med,2007,356(8):800-808
43 Koopman M.Venderbosch S.Van Tinteren H,etal.Predictive and prognosticmakers for the outcome of chemotherapy in advanced colorectal cancer,aretrospective analysis of the phase III randomised CAIRO study[J].Eur J Cancer,2009,45(11):1999-2006
44 Darcy KM,Tian C,Reed E.A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision repair Cross-Complementation Group 1 Expression in Optimal,Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy[J].CanCer Res,2007, 67(9): 4474 -4481
45徐大洲,茅国新.ERCC1在胃癌中的表达及预后意义.交通医学,2010,24(4):375-380
46唐琳,梁军,李玉军.上皮性卵巢癌ERCC1表达与顺铂化疗耐药的关系[J].齐鲁医学杂志.2009,24(5):388-390
47王会妍,瞿全新.卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展,2006,15(7):512-514
48 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene pyoducts [J] .CanCer Res,1995,55:968-970
49 Olaussen KA,Dunant A,Fouret P,etal.DNA repair by ERCC1 in non-small-cell lung Cancer and cisplatin-based adjuvant chemotherapy [J].N Eng1 J Med,2006,355(10):983-991
50阴冠程,元春花,刘君,等.多药耐药基因MDR1在大肠癌的表达及意义.泰山医学院学报,2007,28:32-34
51 Izquierdo MA,Vander Zee AG,Vermorken JB,eta1.Drug reted marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J].J Natl Cancer Inst,1995,87(16):1230-1237
52梁川,吴绪峰,陈慧君.卵巢癌中MDR1的表达及其临床意义.肿瘤防治研究,2008,35(10):723-726
53 Baekelandt MM,Holm R,Nesland JM,eta1.P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advance ovarian cancer[J].Anticancer Res,2000,20(2B):l1061-1067
54王绍娟,魏萍,李家梅,等.卵巢癌基因表达与化疗疗效及预后相关性的研究.临床和实验医学杂志,2006,5(10):1548-1549
55张素娟,闫洪超,薛加强. MDR1基因在上皮性卵巢癌组织中的表达及临床意义.实用诊断与治疗杂志,2007 ,21(7):515-516
56 Krasznai ZT,Friedlander E,Nsgy A,eta1.Quantitative and runetional assay of MDRI/P170-modiated MDR in aseites cells of patients with ovarian cancer.Anticancer Res.2005,25(2A):1187-1192
57 Hille S,Rein DT,Riffelmann M.Anticancer drugs induce mdrl gene expression in recurrent ovarian cancer[J].Anticancer Drugs,2006, 17(9) :1041-1044
58 Ozalp SS,Yalcin OT,Tanir M,etal.Mutidrug resistance geng-1(P-gp) expres-sion in epithelial ovarian malignancies[J].Eur J GynecoL Oncol. 2002.23(4): 337-340
59 Materna V,Pleger J,Hoffmann U,eta1.RNA expression of MDRl/P- glycopr-otein,DNA-topoisomerase I,and MRP2 in ovarian carcinoma patients: correla-tion with chemotherapeutic response[J]. Gynecol Oncol,2004, 94(1):152-160
60 Penson RT,Oliva E,Skates SJ,etal.Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients:a study in serim samples[J].Gyneeol Oncol,2004, 93(1):98-106
61 Maurice-Duelli A, Ndoye A, Bouali S, etal. Enhanced cell grow thinhibition following PTEN nonviral gene transferusing polyethylenimine and photochemical in tern alization in endometrial cancer cells[J].Technol Cancer Res Treat, 2004, 3( 5 ) :459-466
62 Khan S,Kumagai T,Vora J,etal. PTEN promoter is methylated in a proportion of invasive breast cancers [J] .Int J Cancer 2004,112 (3): 407- 410
63 Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor out come in breast cancer[J].Mod Pathol, 2001,14( 7):672-676
64 Rustia A,Wierzbicki V,Marrocco L,etal.Is exon 5 of the PTEN MMAC1 gene a prognostic marker in anaplastic glioma[J].Neurosurg Rev,2001, 24(2):97-102
65李锁严,杨薇薇,温秋婷,等. PTEN和HIF-1α在卵巢浆液性肿瘤中的表达及其相关性的研究.赤峰学院学报(自然科学版),2009,25(9):99-101
66曾俐琴,段振玲,彭芝兰.上皮性卵巢癌组织中PTEN和P-Akt蛋白的表达及其临床意义.山西医科大学学报,2008,49(1):75-77
67马鹏,曹晓燕,冯义朝.PTEN蛋白表达与胃癌预后的关系.延安大学学报(医学科学版),2010,8(2):1-2
68朱巧英,沈宇飞,胡建铭,等.卵巢上皮性肿瘤中PTEN的表达及临床意义.江苏医药,2009,35(11):1258-1259
69陈颖,李建军,杨雪飞,等. PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意义.中国医科大学报,2004,33(2):156-158
70黄海玉,刘小乐,陈衡,等.PTEN和FHIT在上皮性卵巢肿瘤中的表达及其临床意义.中国妇幼保健,2010,25:654-656
71 WAITE K A,ENG C.Protein PTEN:Form and Function[J].AmJ Hum Genet,2002,70(4):829-844
72顾建建. PTEN基因及其在卵巢癌巾的研究进展.中国肿瘤,2006,15(9):604-606
73 Walte KA,Eng C.Protein PTEN:form and function[J]. Am J Hum Genet,2002,70(3):829-844
74 Rustia A,Wierzbicki V,Marroceo L,etal. Is exon 5 of the PTEN MMACI gene a prognostic marker in anaplastic glioma[J]. Neurosurg Rev,2001,24(2):97-102
75 Lin JH,Deng G,Huang Q,etal.KIAP,a novelmember of the inhibitor of apoptosis protein family[J].Biochem Biophys Res Commun,2000,279 (3) :820-831
76 Vucic D,Stennicke HR,Pisabarro MT,etal.ML-IAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas [J].CurrBiol,2000,10 (21) :1359-1366
77 Ashhab Y,Alian A,Polliae A,etal.Two spilicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern [J]. FEBS Lett,2001,495 (122) :56-60
78 Gazzaniga P,Gradilone A,Giuliani L,etal.Expression and prognostic significance of LIVIN,SURVIVIN and other apoptosis related genes in the progression of superficial bladder cancer [J].Ann Oncol,2003,14(1):85-90
79 Nedelcu T,Kubista T,Koller A.Livin and Bcl22 expression in high-grade osteosarcoma [ J ]. J Cancer Res Clin Oncol,2008,134(2):237-244
80 Kempkensteffen C,Hinz S,Christoph F,etal.Expression of the Apoptosis Inhibitor Livin in Renal Cell Carcinomas:Correlations with Patholog and Outcome[J].Tumour Biol.2007,28(3):132
81 Xiang Y,Yao H,Wang S,etal.Prognostic value of Survivin and Livin in nasopharyngeal carcinoma[J].Laryngoscope,2006,116(1):126
82张健,王雪松,李洪运.凋亡抑制基因Livin在人胃癌组织中的表达及临床意义.实用肿瘤杂志,2010,25(5):546-548
83李莉,曹博淦,王丽娜,等. Linvin基因在非小细胞肺癌组织中的表达及临床意义.现代肿瘤医学,2010,18(12):2366-2367
84祝兴旺,张明明,宋永胜.凋亡抑制蛋白livin在膀胱移行细胞癌中表达及临床意义.中华实用诊断与治疗杂志,2009,23(2):121-123
85张强,高岩,王新立,等.食管鳞癌组织中PTEN、Livin蛋白的表达变化及意义.山东医药,2010,50(18):52-53
1 JIAO Yi-sheng,WANG Yong-lai,etal.The expression and significance of Livin and Smac in epithelial ovarian carcinoma tissues[J].Modern Oncology 2009,17(2):296-299
2 Andrea J E,Adachi K,Morgan AR.Fluorometric assays for DNA topoisomerases and topoisomerase targeted drugs;quantitation of catalytic activity and DNA clearage [J].Mol Pharmacol,1991,40(4):495-501
3 Nelson WG,Liu LF,Coffey DS.Newly replicated DNA is associated with DNA topisomerase II in cultured rat prostatic adenocarcinoma cells[J].Nature,1986, 322(6075):187-189
4陈军,王纳.抗肿瘤药物作用的重要靶点-DNA拓扑异构酶[J].国外医学肿瘤学分册,1995,22(5):271-273
5 Yabuki N,Sasano H,Kato K etal.Immunohistochemical study of DNA topisomerase II In human gastric disorder,Am J Pathol,1996,149:997-1007
6邓刚,杨成章,陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义,临床耳鼻喉科杂志,2005,19(9):396-398
7李玉艳,李志裕,王华,等.拓扑异构酶与抗癌药[J].药学进展,1996,20 (3):138-142
8 Nooter K,Sonneveld P.Clinical relevance of P-glycoprotein expression in haematological malignancies.Leuk Res,1994,18 (4):233
9 Grabowski DR,Dubyak GR,Rybicki L,etal.Tumor cell resistance to topoisomeraseII poisons:role for intracellular free calcium in the sensitization byinhibitors or calciumcalmodulin-dependent enzymes[J]. Biochem Pharmacol,1996, 56(3):345-349
10 Boven E,Jansen WJ,Hulscher TM,etal.The influence of P170- glycoprotein modul-Ators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/MDR 1.1 human melanomaxenografts[J].Eur J Cancer, 1995, 35(5):840-849
11冯建航,许艳丽,李恩民.核基质成分-拓扑异构酶II与肿瘤耐药.肿瘤防治杂志,2001,8(6):675-677
12 Ito K,Yabuki N,Sasano H,etal.Immunohistochemical study of Ki67 and DNA topisomerase II In human endometrium[J],Mod Pathol,1997, 10(4): 289-294
13郭威,宋光,吴国新,等.GST-P、P-gp及TOPOII在大肠癌中的表达及其多药耐药的临床研究.齐齐哈尔医学院学报,2007,28(3):269-272.
14 Gotlieb WH,Goldberg I,Weise B,etal. Topoisomerase II Immunostaining as a Prognostic maker for survival in ovarian cancer[J].Gynecol Oncol, 2001, 82(1):99-104
15傅士龙,张国玲,李子庭,等.卵巢癌拓扑异构酶TOPOIIα表达与化疗敏感性的关系.现在妇产科进展,2002,11(4):245-247
16邓刚,杨成章,陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义.临床耳鼻咽喉科杂志.2005,19(9):396-398
17 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene pyoducts [J] .Cancer Res,1995,55:968-970
18 Saebo M,Skjelbred CF,Nexo BA.Indreased mRNA expression levels of ERCC1,OGG1 and RAI in colorectal adenmas and carcinomas[J].BMC Cancer,2006,6:208
19 Doig J,Anderson C,Lawrence NJ,etal.Mice with skinspecific DNA repair gene(ERCC1)inactivation are hypersensitive to ultraviolet irradiation induced skin cancer and show more rapid actinic progression[J]. Oncogene,2006, 25(47): 6229-6238
20韩为浓,李虹,谢鹭,等。人鼻咽与鼻咽癌cDNA阵谱中DNA修复相关基因表达差异的初步研究[J].中华肿瘤杂志,2002,24(2):114-117
21 Fautrel A,Andrieux L,Musso O,etal.Overexpression of the two nucleotide excision Repair genes ERCC1 and XPC in human hepatocellular carcinoma[J].J Hepatol,2005, 43(2):288-293
22 Taillade L,Penault-Llorca F,Boulet T,etal.Immunohistochemichal expression of Biomarkers:a comparative study between diagnostic bronchial biopsies and surgical Specimens of non-smallcell lung cancer[J].Ann Oncol,2007,18(6):1043-1050
23 Chen P,Wiencke J,Aldape K,etal.Association of an ERCC1 polymorphism with adult onset glioma[J].Cancer Epidemiol Biomarkers Prev,2000, 9(8):843-847
24 Zamble DB,Lippard SJ.Cisplatin and DNA repair in cancer chemotherapy[J].Trend Biochem Sci,1995,20(10):435-439
25 Ahaha R,Liang X,Yu JJ,etal.Excision repair cross complementing group
1:gene expression and platinum resistance[J].Int J MolMed,2004, 14(6):959-970
26刘郭艳,瞿全新,糜若然,等.RNA干扰技术抑制切除修复交叉互补基因1对卵巢上皮性癌细胞顺铂敏感性的影响[J].中华妇产科杂志,2006,41(5):339-342
27张树荣,李荷莲,乐杰.卵巢癌耐药机制研究进展[J].实用妇产科杂志,2006,22(3):148-150
28唐琳,梁军,李玉军.上皮性卵巢癌ERCC1表达与顺铂化疗耐药的关系[J].齐鲁医学杂志.2009,24(5):388-390
29蒋胜,李力,张玮,等.ERCC1基因mRNA表达水平在卵巢癌上皮性癌组织中的意义.实用妇产科杂志.2009,25(11):661-663
30 Olaussen KA,Dunant A,Fouret P,etal.DNA repair by ERCC1 in non-small-cell lung Cancer and cisplatin-based adjuvant chemotherapy [J] .N Eng1 J Med,2006,355(10):983-991
31 Handra-Luca A,Hernandez J,Mountios G,etal.Imaging, Diagnosis, Prognosis excision repair cross complementation group 1 immunohisto- chemical expression predicts objective response and cancer specific survival in patients treated by cisplatin based induction chemotherapy for locally advanced head and neck spuamous cell carcinoma[J].Clin Cancer Res,2007,13(13),3855-3859
32王会妍,瞿全新.卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展,2006,15(7):512-514
33 Kwon HC,Roh MS,Oh SY,etal.Prognostic value of expression of ERCC1,thymidylate synthase,and glutathions S-transferase P1 for 5-fluorouracil oxaliplatin chemotherapy in advanced gastric cancer[J].Ann Oncol,2007,18(3):504-509
34李琳,许崇安,田大力,等.非小细胞肺癌组织ERCC1表达及其与预后相关性的分析.中华肿瘤防治杂志,2010,17(3):186-190
35丁征平,张杰,邵晋晨. ERCC1表达对I期非小细胞肺癌患者术后生存率的影响.中国肺癌杂志,2010,13(5):522-525
36 Ceppi P,Volante M,Novello S,etal.ERCC1 and RRM1 gene expressions but EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cispltin and gemcitabine[J].Ann Oncol,2006,17(12):1818-1825
37 Azuma K,Komohara Y,Sasada T,etal. Excision repair crosscomplem- entation group 1 predicts progression-free and overall survival innon-small cell lung cancer patients treated with platinumbased chemotherapy [J].Cancer Sci,2007,98(9):1336-1343
38 Zheng Z,Chen T,Li X,etal.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer[J]. N Engl J Med,2007,356(8):800-808
39 Simth S,Su D,Rigault de la Longrais IA,etal.ERCC1 genotype and phenotype in epithlial ovarian cancer identify pantients likely to benefit from paclitaxel treatment in addition to platinim-based therapy[J].J Clin Oncol,2007,25(33):5172-5179
40 Koopman M,Venderbosch S,Van Tinteren H,etal.Predictive and prognostic makers for the outcome of chemotherapy in advanced colorectal cancer,a retrospective analysis of the phase III randomised CAIRO study[J].Eur J Cancer,2009,45(11):1999-2006
41 Darcy KM,Tian C,Reed E.A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision repair Cross- complementation Group 1 Expression in Optimal,Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy[J].CanCer Res,2007,67(9): 4474-4481
42 Galani E,Skarlas D,Sgouros J,etal.Dionyssiou-Asterion A.Cormlation of MDR1 expression and CA125 in ovarian cancer.In.vivo,2005, 19(4):797-800
43 Wang Z,Xie Y,Wang H.Changes in Survivin Messenger RNA Level during Chemotherapy treatment in Ovarian Cancer Cells.Cancer Biol Ther,2005,4(7):716-719
44 Vander Holt B, Vanden Heuvel-Eibrink MM, VanSchaik RH, etal. ABCBI gene polym- orphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients[J].Clin PharmacolTher, 2006, 80: 427-443
45 Gregory D,Ieonard J,Tito F.The role of ABC transporters in clinical practice[J]. Oncologist,2003,8(4): 411
46 Coley HM.Mechanisms and strategies to overcome chemothe- rapy resistance in metastatic breast cancer[J]. Cancer Treat Rev,2008,34(4):378-390
47许景风.肿瘤细胞MDR1基因多药耐药的研究进展.解放军药学学报，2010，26（5）：453-455
48张素娟，闫洪超，薛加强. MDR1基因在上皮性卵巢癌组织中的表达及临床意义.实用诊断与治疗杂志，2007，21（7）：515-516
49 Krasznai ZT,Friedlander E,Nsgy A,eta1.Quantitative and runetional assayof MDRI/P170-modiated MDR in aseites cells of patients with ovariancancer．Anticancer Res.2005,25(2A):1187-1192
50崔洁，刘新兰，何涛.乳腺癌组织中耐药基因MDR1、BCRP、LRP的研究进展.宁夏医学杂志，2009，31（5）：469-471
51 Baekelandt MM,Holm R,Nesland JM,eta1.P-glycoprotein expression is amarker for chemotherapy resistance and prognosis in advance ovariancancer[J].Anticancer Res,2000,20(2B):l061-1067
52 Weinstein RS,Jakat SM,Donimgues:JM,et al.Relation ship of theexpression of the multidrug resistance gene product (P-Glycoprotein)inhumomcoloncarcinoma to local tumor aggressiveness and Lymphodemotestasis[J].Ganeer Res,1991,51:2720
53王绍娟，魏萍，李家梅，等.卵巢癌基因表达与化疗疗效及预后相关性的研究.临床和实验医学杂志，2006，5（10）：1548-1549
54 Izquierdo MA,Vander Zee AG,Vermorken JB,eta1.Drug reted marker Lrpfor prediction of response to chemotherapy and prognoses in advancedovarian carcinoma [J].J Natl Cancer Inst,1995,87(16):1230-1237
55 Steck PA,Pershouse MA,Jzsser SA,etal.Identification of a candidatetumour suppressor gene, MMAC1,at chromosome 10q23.3 that is mutatedin multiple advanced cancers[J].Nat Genet,1997,15(4) : 356-363
56 Li J,Yen C,Liaw D,etal. PTEN, a putative protein tyrosin ephosphatasegene mutated in human brain,breast,and prostate cancer[J]. Science,1997,275(5308):1943-1947.
57 Li DM,Sun H.TEP1,encoded by a candidate tumor suppressor locus,is anovel protein tyrosine phosphatase regulated by transforming growthfactor beta[J].Cancer Res,1997,57(11):2124-2129
58 Simpson L,Parsons R.PTEN:life as a tumor suppressor[J].ExpCell Res,2001, 264(1):29-41
59 Hamada K,Sasaki T,Koni PA,etal.The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis[J].Genes Dev,2005,19(17):2054-2065
60 Datta SR, Brunet A,Greenberyg ME.Cellular survival:a play in three Akts. Genes Dev,1999,13(22):2905-2927
61 Tamura M,Gu J, Matsumoto K,etal.Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN. Science,1998, 280: 1614-1617
62陈颖,李建军,杨雪飞,等. PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意义.中国医科大学学报,2004,33(2):156-158
63 Lee JS,Choi YD,Choi C,eta1.Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth[J].Anal Quant Cytol Histol,2005,27(4):202-210
64 Schondoff T,Gohring UJ,Roth G,eta1.Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients[J].Eur J Clin Invest,2003,33(3):256-260
65 Ashhab Y,Alian A,Polliack A,etal.Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern[J].FEBS Lett,2001,495(1-2):56
66 Yagihashi A,Ohmura T,Asanuma K,etal.Detection of autoantibodies to survi vin and livin in sera from patients with breast cancer. Clin Chim Acta, 2005, 362: 125-130
67 Yagihashi A, Asanuma K, Kobayashi D, etal.Detection of autoantibodies to livin and survivin in sera from lung cancer, patients .Lung cancer 2005, 48 (2):217-221
68 Sanna MG,Silva CJ,Ducrey O,etal.IAP suppression of apoptosis involves distinct mechanisms:The TAK1/JNK1 signaling cascade and caspase inhibition[J].Mol Cell Bid,2002,22(6):1754
69 Ma L,Huang Y,Song Z,etal.Livin promotes Smac/DIABLO degradation byubiquitin proteasome pathway[J].Cell Death Differ,2006, 13(12): 20792-20881
70 Naehmias B,Ashhab Y,Bucholtz V,etal.Caspase-mediated cleavage Converts Livin from an antiapoptotic to a proapoptotic factor:implications for drug-resistant melanoma[J].Cancer Res,2003,63(19):6340
71李百鸥,王永来.凋亡抑制蛋白Livin在卵巢癌中的表达.山东医药,2008,48(14):51
2焦伊胜,王永来,张淑兰,等. Livin、Smac在上皮性卵巢癌中的表达及意义.妇科肿瘤,2009,17(2):296-299
3 Qazi F,McGuire WP.The treatment of epithlial ovarian cancer.CA cancer JClin,1995,45:88
4郄明蓉,张崇淑,杨小芸,等.10年间卵巢上皮性癌的治疗及预后因素分析[J].华西医学,2002(3):312-314
5周凤志,陈毅男,张国男,等.不同年龄段卵巢上皮性癌的临床病理分析[J].四川肿瘤防治,2003(4):197-200
6宋水勤,张国楠,吴艳丽,等.卵巢上皮性癌生存率及预后因素分析[J].现代妇产科进展,2001(4):250-253
7张洁清,余冬青,李力,等.影响卵巢癌预后的多因素分析.广西医科大学学报,2004,21(5):687-689
8关珊,李永辉,宋鸿碧,等.上皮性卵巢癌生存率及预后因素分析.贵阳医学院学报.2007,32(2):177-178
9张桂荣,翟云起,杜少敏,等.卵巢上皮癌治疗及预后影响因素研究[ J].肿瘤学杂志, 2003(2) : 68- 70
10 Mackay HJ,Brady MF,Oza AM, etal. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010 Aug;20(6):945-52
11臧荣余,张志毅,李子庭,等.晚期上皮性卵巢癌的预后影响因素.复旦学报(医学科学版),2001,28(1):47-50
12王世阆,张崇淑,彭红琪,等. 135例卵巢上皮癌的治疗及其预后因素.中华妇产科杂志,1991,26: 86
13 Clark TG,Stew art ME,Altman DG,etal.A prognostic model for ovarian cancer.B r J Cancer,2001,85(7):944-952
14 Brun JL,Feyler A,Chene G,etal.Long term results and prognostic factors in patients With epithelial ovarian cancer.Gynecol Oncol,2000,78(1):21-27
15罗中明,郭振仪,阮晓红,等.晚期上皮性卵巢癌预后的相关因素分析.临床合理用药,2008,2(16):31-33
16杨幼易,蔡树模.应用Cox模型对上皮性卵巢癌的预后分析.中国医学文摘·肿瘤学,2001,15(3):280-281
17 Petru E,Lahousen M,Tamussino K,etal.Lymphadenectomy in stage 1 ovarian cancer. Am J Obstet Gynecol,1994,170(2):656-662
18 Parazzini F,Valsecchi G,Bolis G,etal.Pelvic and paraortic lymphnodal status in advanced ovarian cancer and survival.Gynecol Oncol,1999,74(1):7-11
19 Scarabelli C,Gallo A,Zamelli A,etal.Systematic pelvic and paraorticlymphadenectomy during cytoreductive surgery in advanced ovanrian cancer:potential benefit on survival. Gynecol Oncol,1995,58(3):417
20熊宙芳,王泽华,王世宣.卵巢上皮性癌的腹膜后淋巴结切除对预后的影响.中华妇产科杂志, 2003, 38 (2) : 77-80
21 Kikkawa F,Ishikawa H,Tamakoshi K,etal.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995, 60(4):227-231
22 Soygili I,Gnclu S,CsJu T,etal.Does Systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma?A DEGOG Study. J Surg Oncol,2002,81(3):132-137
23 Barber HRK.Symposium on ovarian tumors:foreword[J].Clin Obstet Gynecol,1996,12:929
24王建.上皮性卵巢癌预后因素分析.天津医科大学学报,2005,11(2):260
25 Bristow TE,Tomacruz TS,A rmstrong DK,etal. Survival effect of maximal cyto reductive surgery for advanced ovarian carcinoma during the platinumera:A meta analysis. J Clin O nco l,2002,20 (5):1248-1259
26吴玉,王秋宇.46例上皮性卵巢癌的临床及预后分析.中国实用医药,2008,3(1):90-91
27关珊,宋鸿碧,文萍,等.术后化疗对上皮性卵巢癌预后的影响.贵阳医学院学报,2006,31(6):563-566
28 Ito K,Yabuki N,Sasano H,etal.Immunohistochemical study of Ki67 and DNA topisomerase II in human endometrium [J],Mod Pathol,1997, 10(4): 289-294
29傅士龙,张国玲,李子庭,等.卵巢癌拓扑异构酶TOPOIIα表达与化疗敏感性的关系.现在妇产科进展,2002,11(4):245-247
30 30Gotlieb WH,Goldberg I,Weise B,etal.Topoisomerase II Immunostaining as a Prognostic maker for survival in ovarian cancer[J].Gynecol Oncol, 2001,82(1):99-104
31卢培刚,朱树干,刘玉光.DNA拓扑异构酶II在人脑胶质瘤中的表达及临床意义.中国神经精神疾病杂志,2002 ,28(5):380-381
32郭威,宋光,吴国新,等.GST-P、P-gp及TopoII在大肠癌中的表达及其多药耐药的临床研究.齐齐哈尔医学院学报，2007，28（3）：269-271
33邓刚，杨成章，陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义.临床耳鼻咽喉科杂志.2005,19（9）：396-398
34邹倩,石王伟,黄利鸣，等.拓扑异构酶 在宫颈癌组织中的表达及其临床意义.肿瘤防治研究，2003，30（3）：196-197
35 Andrea JE,Adachi K,Morgan AR.Fluorometric assays for DNA topoisomerasesand topoisomerase targeted drugs;quantitation of catalyticactivity and DNA clearage [J].Mol Pharmacol,1991,40 (4):495-501
36 Staley BE,Samowitz WS,Bronstein IB,etal.Expression of DNAtopoisomerase I and DNA topoisomerase II-alpha in carcinoma of thecolon[J] .Mod Pathol,1999,12 (4):356-361
37蒋胜，李力，张玮，等.ERCC1基因mRNA表达水平在卵巢癌上皮性癌组织中的意义.实用妇产科杂志.2009,25(11)：661-663
38 Simth S,Su D,Rigault de la Longrais IA,etal.ERCC1 genotype andphenotype in epithlial ovarian cancer identify pantients likely to benefitfrom paclitaxel treatment in addition to platinim-based therapy[J].J ClinOncol,2007,25(33):5172-5179
39李琳，许崇安，田大力，等.非小细胞肺癌组织ERCC1表达及其与预后相关性的分析.中华肿瘤防治杂志，2010，17（3）：186-190
40 Ceppi P,Volante M,Novello S,etal.ERCC1 and RRM1 gene expressions butEGFR are predictive of shorter survival in advanced non-small-cell lungcancer treated with cispltin and gemcitabine[J]. Ann Oncol,2006,17(12) :1818-1825
41 Azuma K,Komohara Y,Sasada Z,etal. Excision repair crosscomplementation group 1 predicts progression-free and overall survival in non-smallcelllung cancer patients treated with platinumbased chemotherapy[J].Cancer Sci,2007,98(9):1336-1343
42 Zheng Z,Chen T,Li X,etal. DNA synthesis and repair genes RRM1 andERCC1 in lung cancer[J]. N Engl J Med,2007,356(8):800-808
43 Koopman M.Venderbosch S.Van Tinteren H,etal.Predictive and prognosticmakers for the outcome of chemotherapy in advanced colorectal cancer,aretrospective analysis of the phase III randomised CAIRO study[J].Eur J Cancer,2009,45(11):1999-2006
44 Darcy KM,Tian C,Reed E.A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision repair Cross-Complementation Group 1 Expression in Optimal,Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy[J].CanCer Res,2007, 67(9): 4474 -4481
45徐大洲,茅国新.ERCC1在胃癌中的表达及预后意义.交通医学,2010,24(4):375-380
46唐琳,梁军,李玉军.上皮性卵巢癌ERCC1表达与顺铂化疗耐药的关系[J].齐鲁医学杂志.2009,24(5):388-390
47王会妍,瞿全新.卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展,2006,15(7):512-514
48 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene pyoducts [J] .CanCer Res,1995,55:968-970
49 Olaussen KA,Dunant A,Fouret P,etal.DNA repair by ERCC1 in non-small-cell lung Cancer and cisplatin-based adjuvant chemotherapy [J].N Eng1 J Med,2006,355(10):983-991
50阴冠程,元春花,刘君,等.多药耐药基因MDR1在大肠癌的表达及意义.泰山医学院学报,2007,28:32-34
51 Izquierdo MA,Vander Zee AG,Vermorken JB,eta1.Drug reted marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J].J Natl Cancer Inst,1995,87(16):1230-1237
52梁川,吴绪峰,陈慧君.卵巢癌中MDR1的表达及其临床意义.肿瘤防治研究,2008,35(10):723-726
53 Baekelandt MM,Holm R,Nesland JM,eta1.P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advance ovarian cancer[J].Anticancer Res,2000,20(2B):l1061-1067
54王绍娟,魏萍,李家梅,等.卵巢癌基因表达与化疗疗效及预后相关性的研究.临床和实验医学杂志,2006,5(10):1548-1549
55张素娟,闫洪超,薛加强. MDR1基因在上皮性卵巢癌组织中的表达及临床意义.实用诊断与治疗杂志,2007 ,21(7):515-516
56 Krasznai ZT,Friedlander E,Nsgy A,eta1.Quantitative and runetional assay of MDRI/P170-modiated MDR in aseites cells of patients with ovarian cancer.Anticancer Res.2005,25(2A):1187-1192
57 Hille S,Rein DT,Riffelmann M.Anticancer drugs induce mdrl gene expression in recurrent ovarian cancer[J].Anticancer Drugs,2006, 17(9) :1041-1044
58 Ozalp SS,Yalcin OT,Tanir M,etal.Mutidrug resistance geng-1(P-gp) expres-sion in epithelial ovarian malignancies[J].Eur J GynecoL Oncol. 2002.23(4): 337-340
59 Materna V,Pleger J,Hoffmann U,eta1.RNA expression of MDRl/P- glycopr-otein,DNA-topoisomerase I,and MRP2 in ovarian carcinoma patients: correla-tion with chemotherapeutic response[J]. Gynecol Oncol,2004, 94(1):152-160
60 Penson RT,Oliva E,Skates SJ,etal.Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients:a study in serim samples[J].Gyneeol Oncol,2004, 93(1):98-106
61 Maurice-Duelli A, Ndoye A, Bouali S, etal. Enhanced cell grow thinhibition following PTEN nonviral gene transferusing polyethylenimine and photochemical in tern alization in endometrial cancer cells[J].Technol Cancer Res Treat, 2004, 3( 5 ) :459-466
62 Khan S,Kumagai T,Vora J,etal. PTEN promoter is methylated in a proportion of invasive breast cancers [J] .Int J Cancer 2004,112 (3): 407- 410
63 Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor out come in breast cancer[J].Mod Pathol, 2001,14( 7):672-676
64 Rustia A,Wierzbicki V,Marrocco L,etal.Is exon 5 of the PTEN MMAC1 gene a prognostic marker in anaplastic glioma[J].Neurosurg Rev,2001, 24(2):97-102
65李锁严,杨薇薇,温秋婷,等. PTEN和HIF-1α在卵巢浆液性肿瘤中的表达及其相关性的研究.赤峰学院学报(自然科学版),2009,25(9):99-101
66曾俐琴,段振玲,彭芝兰.上皮性卵巢癌组织中PTEN和P-Akt蛋白的表达及其临床意义.山西医科大学学报,2008,49(1):75-77
67马鹏,曹晓燕,冯义朝.PTEN蛋白表达与胃癌预后的关系.延安大学学报(医学科学版),2010,8(2):1-2
68朱巧英,沈宇飞,胡建铭,等.卵巢上皮性肿瘤中PTEN的表达及临床意义.江苏医药,2009,35(11):1258-1259
69陈颖,李建军,杨雪飞,等. PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意义.中国医科大学报,2004,33(2):156-158
70黄海玉,刘小乐,陈衡,等.PTEN和FHIT在上皮性卵巢肿瘤中的表达及其临床意义.中国妇幼保健,2010,25:654-656
71 WAITE K A,ENG C.Protein PTEN:Form and Function[J].AmJ Hum Genet,2002,70(4):829-844
72顾建建. PTEN基因及其在卵巢癌巾的研究进展.中国肿瘤,2006,15(9):604-606
73 Walte KA,Eng C.Protein PTEN:form and function[J]. Am J Hum Genet,2002,70(3):829-844
74 Rustia A,Wierzbicki V,Marroceo L,etal. Is exon 5 of the PTEN MMACI gene a prognostic marker in anaplastic glioma[J]. Neurosurg Rev,2001,24(2):97-102
75 Lin JH,Deng G,Huang Q,etal.KIAP,a novelmember of the inhibitor of apoptosis protein family[J].Biochem Biophys Res Commun,2000,279 (3) :820-831
76 Vucic D,Stennicke HR,Pisabarro MT,etal.ML-IAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas [J].CurrBiol,2000,10 (21) :1359-1366
77 Ashhab Y,Alian A,Polliae A,etal.Two spilicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern [J]. FEBS Lett,2001,495 (122) :56-60
78 Gazzaniga P,Gradilone A,Giuliani L,etal.Expression and prognostic significance of LIVIN,SURVIVIN and other apoptosis related genes in the progression of superficial bladder cancer [J].Ann Oncol,2003,14(1):85-90
79 Nedelcu T,Kubista T,Koller A.Livin and Bcl22 expression in high-grade osteosarcoma [ J ]. J Cancer Res Clin Oncol,2008,134(2):237-244
80 Kempkensteffen C,Hinz S,Christoph F,etal.Expression of the Apoptosis Inhibitor Livin in Renal Cell Carcinomas:Correlations with Patholog and Outcome[J].Tumour Biol.2007,28(3):132
81 Xiang Y,Yao H,Wang S,etal.Prognostic value of Survivin and Livin in nasopharyngeal carcinoma[J].Laryngoscope,2006,116(1):126
82张健,王雪松,李洪运.凋亡抑制基因Livin在人胃癌组织中的表达及临床意义.实用肿瘤杂志,2010,25(5):546-548
83李莉,曹博淦,王丽娜,等. Linvin基因在非小细胞肺癌组织中的表达及临床意义.现代肿瘤医学,2010,18(12):2366-2367
84祝兴旺,张明明,宋永胜.凋亡抑制蛋白livin在膀胱移行细胞癌中表达及临床意义.中华实用诊断与治疗杂志,2009,23(2):121-123
85张强,高岩,王新立,等.食管鳞癌组织中PTEN、Livin蛋白的表达变化及意义.山东医药,2010,50(18):52-53
1 JIAO Yi-sheng,WANG Yong-lai,etal.The expression and significance of Livin and Smac in epithelial ovarian carcinoma tissues[J].Modern Oncology 2009,17(2):296-299
2 Andrea J E,Adachi K,Morgan AR.Fluorometric assays for DNA topoisomerases and topoisomerase targeted drugs;quantitation of catalytic activity and DNA clearage [J].Mol Pharmacol,1991,40(4):495-501
3 Nelson WG,Liu LF,Coffey DS.Newly replicated DNA is associated with DNA topisomerase II in cultured rat prostatic adenocarcinoma cells[J].Nature,1986, 322(6075):187-189
4陈军,王纳.抗肿瘤药物作用的重要靶点-DNA拓扑异构酶[J].国外医学肿瘤学分册,1995,22(5):271-273
5 Yabuki N,Sasano H,Kato K etal.Immunohistochemical study of DNA topisomerase II In human gastric disorder,Am J Pathol,1996,149:997-1007
6邓刚,杨成章,陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义,临床耳鼻喉科杂志,2005,19(9):396-398
7李玉艳,李志裕,王华,等.拓扑异构酶与抗癌药[J].药学进展,1996,20 (3):138-142
8 Nooter K,Sonneveld P.Clinical relevance of P-glycoprotein expression in haematological malignancies.Leuk Res,1994,18 (4):233
9 Grabowski DR,Dubyak GR,Rybicki L,etal.Tumor cell resistance to topoisomeraseII poisons:role for intracellular free calcium in the sensitization byinhibitors or calciumcalmodulin-dependent enzymes[J]. Biochem Pharmacol,1996, 56(3):345-349
10 Boven E,Jansen WJ,Hulscher TM,etal.The influence of P170- glycoprotein modul-Ators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/MDR 1.1 human melanomaxenografts[J].Eur J Cancer, 1995, 35(5):840-849
11冯建航,许艳丽,李恩民.核基质成分-拓扑异构酶II与肿瘤耐药.肿瘤防治杂志,2001,8(6):675-677
12 Ito K,Yabuki N,Sasano H,etal.Immunohistochemical study of Ki67 and DNA topisomerase II In human endometrium[J],Mod Pathol,1997, 10(4): 289-294
13郭威,宋光,吴国新,等.GST-P、P-gp及TOPOII在大肠癌中的表达及其多药耐药的临床研究.齐齐哈尔医学院学报,2007,28(3):269-272.
14 Gotlieb WH,Goldberg I,Weise B,etal. Topoisomerase II Immunostaining as a Prognostic maker for survival in ovarian cancer[J].Gynecol Oncol, 2001, 82(1):99-104
15傅士龙,张国玲,李子庭,等.卵巢癌拓扑异构酶TOPOIIα表达与化疗敏感性的关系.现在妇产科进展,2002,11(4):245-247
16邓刚,杨成章,陈望燕.Ki67和拓扑异构酶IIα在喉鳞状细胞癌中的表达及意义.临床耳鼻咽喉科杂志.2005,19(9):396-398
17 Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene pyoducts [J] .Cancer Res,1995,55:968-970
18 Saebo M,Skjelbred CF,Nexo BA.Indreased mRNA expression levels of ERCC1,OGG1 and RAI in colorectal adenmas and carcinomas[J].BMC Cancer,2006,6:208
19 Doig J,Anderson C,Lawrence NJ,etal.Mice with skinspecific DNA repair gene(ERCC1)inactivation are hypersensitive to ultraviolet irradiation induced skin cancer and show more rapid actinic progression[J]. Oncogene,2006, 25(47): 6229-6238
20韩为浓,李虹,谢鹭,等。人鼻咽与鼻咽癌cDNA阵谱中DNA修复相关基因表达差异的初步研究[J].中华肿瘤杂志,2002,24(2):114-117
21 Fautrel A,Andrieux L,Musso O,etal.Overexpression of the two nucleotide excision Repair genes ERCC1 and XPC in human hepatocellular carcinoma[J].J Hepatol,2005, 43(2):288-293
22 Taillade L,Penault-Llorca F,Boulet T,etal.Immunohistochemichal expression of Biomarkers:a comparative study between diagnostic bronchial biopsies and surgical Specimens of non-smallcell lung cancer[J].Ann Oncol,2007,18(6):1043-1050
23 Chen P,Wiencke J,Aldape K,etal.Association of an ERCC1 polymorphism with adult onset glioma[J].Cancer Epidemiol Biomarkers Prev,2000, 9(8):843-847
24 Zamble DB,Lippard SJ.Cisplatin and DNA repair in cancer chemotherapy[J].Trend Biochem Sci,1995,20(10):435-439
25 Ahaha R,Liang X,Yu JJ,etal.Excision repair cross complementing group
1:gene expression and platinum resistance[J].Int J MolMed,2004, 14(6):959-970
26刘郭艳,瞿全新,糜若然,等.RNA干扰技术抑制切除修复交叉互补基因1对卵巢上皮性癌细胞顺铂敏感性的影响[J].中华妇产科杂志,2006,41(5):339-342
27张树荣,李荷莲,乐杰.卵巢癌耐药机制研究进展[J].实用妇产科杂志,2006,22(3):148-150
28唐琳,梁军,李玉军.上皮性卵巢癌ERCC1表达与顺铂化疗耐药的关系[J].齐鲁医学杂志.2009,24(5):388-390
29蒋胜,李力,张玮,等.ERCC1基因mRNA表达水平在卵巢癌上皮性癌组织中的意义.实用妇产科杂志.2009,25(11):661-663
30 Olaussen KA,Dunant A,Fouret P,etal.DNA repair by ERCC1 in non-small-cell lung Cancer and cisplatin-based adjuvant chemotherapy [J] .N Eng1 J Med,2006,355(10):983-991
31 Handra-Luca A,Hernandez J,Mountios G,etal.Imaging, Diagnosis, Prognosis excision repair cross complementation group 1 immunohisto- chemical expression predicts objective response and cancer specific survival in patients treated by cisplatin based induction chemotherapy for locally advanced head and neck spuamous cell carcinoma[J].Clin Cancer Res,2007,13(13),3855-3859
32王会妍,瞿全新.卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展,2006,15(7):512-514
33 Kwon HC,Roh MS,Oh SY,etal.Prognostic value of expression of ERCC1,thymidylate synthase,and glutathions S-transferase P1 for 5-fluorouracil oxaliplatin chemotherapy in advanced gastric cancer[J].Ann Oncol,2007,18(3):504-509
34李琳,许崇安,田大力,等.非小细胞肺癌组织ERCC1表达及其与预后相关性的分析.中华肿瘤防治杂志,2010,17(3):186-190
35丁征平,张杰,邵晋晨. ERCC1表达对I期非小细胞肺癌患者术后生存率的影响.中国肺癌杂志,2010,13(5):522-525
36 Ceppi P,Volante M,Novello S,etal.ERCC1 and RRM1 gene expressions but EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cispltin and gemcitabine[J].Ann Oncol,2006,17(12):1818-1825
37 Azuma K,Komohara Y,Sasada T,etal. Excision repair crosscomplem- entation group 1 predicts progression-free and overall survival innon-small cell lung cancer patients treated with platinumbased chemotherapy [J].Cancer Sci,2007,98(9):1336-1343
38 Zheng Z,Chen T,Li X,etal.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer[J]. N Engl J Med,2007,356(8):800-808
39 Simth S,Su D,Rigault de la Longrais IA,etal.ERCC1 genotype and phenotype in epithlial ovarian cancer identify pantients likely to benefit from paclitaxel treatment in addition to platinim-based therapy[J].J Clin Oncol,2007,25(33):5172-5179
40 Koopman M,Venderbosch S,Van Tinteren H,etal.Predictive and prognostic makers for the outcome of chemotherapy in advanced colorectal cancer,a retrospective analysis of the phase III randomised CAIRO study[J].Eur J Cancer,2009,45(11):1999-2006
41 Darcy KM,Tian C,Reed E.A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision repair Cross- complementation Group 1 Expression in Optimal,Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy[J].CanCer Res,2007,67(9): 4474-4481
42 Galani E,Skarlas D,Sgouros J,etal.Dionyssiou-Asterion A.Cormlation of MDR1 expression and CA125 in ovarian cancer.In.vivo,2005, 19(4):797-800
43 Wang Z,Xie Y,Wang H.Changes in Survivin Messenger RNA Level during Chemotherapy treatment in Ovarian Cancer Cells.Cancer Biol Ther,2005,4(7):716-719
44 Vander Holt B, Vanden Heuvel-Eibrink MM, VanSchaik RH, etal. ABCBI gene polym- orphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients[J].Clin PharmacolTher, 2006, 80: 427-443
45 Gregory D,Ieonard J,Tito F.The role of ABC transporters in clinical practice[J]. Oncologist,2003,8(4): 411
46 Coley HM.Mechanisms and strategies to overcome chemothe- rapy resistance in metastatic breast cancer[J]. Cancer Treat Rev,2008,34(4):378-390
47许景风.肿瘤细胞MDR1基因多药耐药的研究进展.解放军药学学报，2010，26（5）：453-455
48张素娟，闫洪超，薛加强. MDR1基因在上皮性卵巢癌组织中的表达及临床意义.实用诊断与治疗杂志，2007，21（7）：515-516
49 Krasznai ZT,Friedlander E,Nsgy A,eta1.Quantitative and runetional assayof MDRI/P170-modiated MDR in aseites cells of patients with ovariancancer．Anticancer Res.2005,25(2A):1187-1192
50崔洁，刘新兰，何涛.乳腺癌组织中耐药基因MDR1、BCRP、LRP的研究进展.宁夏医学杂志，2009，31（5）：469-471
51 Baekelandt MM,Holm R,Nesland JM,eta1.P-glycoprotein expression is amarker for chemotherapy resistance and prognosis in advance ovariancancer[J].Anticancer Res,2000,20(2B):l061-1067
52 Weinstein RS,Jakat SM,Donimgues:JM,et al.Relation ship of theexpression of the multidrug resistance gene product (P-Glycoprotein)inhumomcoloncarcinoma to local tumor aggressiveness and Lymphodemotestasis[J].Ganeer Res,1991,51:2720
53王绍娟，魏萍，李家梅，等.卵巢癌基因表达与化疗疗效及预后相关性的研究.临床和实验医学杂志，2006，5（10）：1548-1549
54 Izquierdo MA,Vander Zee AG,Vermorken JB,eta1.Drug reted marker Lrpfor prediction of response to chemotherapy and prognoses in advancedovarian carcinoma [J].J Natl Cancer Inst,1995,87(16):1230-1237
55 Steck PA,Pershouse MA,Jzsser SA,etal.Identification of a candidatetumour suppressor gene, MMAC1,at chromosome 10q23.3 that is mutatedin multiple advanced cancers[J].Nat Genet,1997,15(4) : 356-363
56 Li J,Yen C,Liaw D,etal. PTEN, a putative protein tyrosin ephosphatasegene mutated in human brain,breast,and prostate cancer[J]. Science,1997,275(5308):1943-1947.
57 Li DM,Sun H.TEP1,encoded by a candidate tumor suppressor locus,is anovel protein tyrosine phosphatase regulated by transforming growthfactor beta[J].Cancer Res,1997,57(11):2124-2129
58 Simpson L,Parsons R.PTEN:life as a tumor suppressor[J].ExpCell Res,2001, 264(1):29-41
59 Hamada K,Sasaki T,Koni PA,etal.The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis[J].Genes Dev,2005,19(17):2054-2065
60 Datta SR, Brunet A,Greenberyg ME.Cellular survival:a play in three Akts. Genes Dev,1999,13(22):2905-2927
61 Tamura M,Gu J, Matsumoto K,etal.Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN. Science,1998, 280: 1614-1617
62陈颖,李建军,杨雪飞,等. PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意义.中国医科大学学报,2004,33(2):156-158
63 Lee JS,Choi YD,Choi C,eta1.Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth[J].Anal Quant Cytol Histol,2005,27(4):202-210
64 Schondoff T,Gohring UJ,Roth G,eta1.Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients[J].Eur J Clin Invest,2003,33(3):256-260
65 Ashhab Y,Alian A,Polliack A,etal.Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern[J].FEBS Lett,2001,495(1-2):56
66 Yagihashi A,Ohmura T,Asanuma K,etal.Detection of autoantibodies to survi vin and livin in sera from patients with breast cancer. Clin Chim Acta, 2005, 362: 125-130
67 Yagihashi A, Asanuma K, Kobayashi D, etal.Detection of autoantibodies to livin and survivin in sera from lung cancer, patients .Lung cancer 2005, 48 (2):217-221
68 Sanna MG,Silva CJ,Ducrey O,etal.IAP suppression of apoptosis involves distinct mechanisms:The TAK1/JNK1 signaling cascade and caspase inhibition[J].Mol Cell Bid,2002,22(6):1754
69 Ma L,Huang Y,Song Z,etal.Livin promotes Smac/DIABLO degradation byubiquitin proteasome pathway[J].Cell Death Differ,2006, 13(12): 20792-20881
70 Naehmias B,Ashhab Y,Bucholtz V,etal.Caspase-mediated cleavage Converts Livin from an antiapoptotic to a proapoptotic factor:implications for drug-resistant melanoma[J].Cancer Res,2003,63(19):6340
71李百鸥,王永来.凋亡抑制蛋白Livin在卵巢癌中的表达.山东医药,2008,48(14):51